The Evidence Investigator analyser, based upon Randox’s award-winning Biochip Array Technology, offers a flexible solution to those scientists interested in maximising the output from their research through the benefits achievable from multiplex analysis.
It’s comprehensive test menu will appeal to researchers from a wide variety of disciplines such as immunology, metabolic/nutritional research, oncology and cardiovascular disease making it an ideal instrument for a core-lab facility. In addition, it now has the ability to consolidate both proteomic and genomic applications onto a single platform with the advent of our molecular diagnostics range of tests.
In 1992, Randox created a concept that would transform laboratory testing; Biochip Array Technology (BAT). The aim of this technology is to provide researchers with as much diagnostic information as possible, faster and more efficiently than traditional methods.
The Food and Drug Association (FDA) cleared Biochip Array Technology which was subsequently granted the prestigious MacRobert Award for Engineering. To date this technology has transformed diagnostics worldwide, saving time and money within the laboratory and allowing for highly accurate and informed clinical decisions.
Biochip Array Technology is a multi-analyte testing platform allowing the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample. It provides a unique platform for assessment of biological samples in a rapid, accurate and easy to use format.
The core of the technology is the Randox biochip, a solid state device onto which antibodies specific to different compounds are immobilised and stabilised; these are defined as discrete test sites. Competitive chemiluminescent immunoassays are employed for the biochip arrays. Light signal generated from each of the test regions on the biochip is simultaneously detected using digital imaging technology and compared to that from a calibration curve.
The biochip surface
The surface of the biochip is chemically coated using a proprietary silanation process which allows for:
Control sites – ensuring reliable QC
Each biochip contains internal control sites, which are always on the same position on every biochip. The control sites have set target levels in order to identify problems. If the levels for these control DTRs fall outside the target levels, an error code will be generated instead of a result. This prevents inaccurate results being reported.
Addition of assay reagents and sample to the biochips
Place in thermoshaker – incubate
Biochip carrier loaded into Evidence Investigator
Automatic imaging and result processing